CANbridge Appoints Vice President of Finance and Controller and Vice President of China Oncology and Business Unit Head

BEIJING, Nov. 13, 2018 /PRNewswire/ -- CANbridge Pharmaceutical Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced that it appointed Jeff Lau as Vice President of Finance and Controller, effective September 10^th, and Fangzhou Cheng, as Vice President of China Oncology and Business Unit Head, effective October 29^th. Ms. Cheng is tasked with building the CANbridge oncology commercial organization, among other things, with a near-term focus on Caphosol® and Nerlynx® launches.  Both are new positions, and represent a considerable strengthening of the executive team as CANbridge continues to ramp up its clinical program and commercial operations.

Jeff Lau has over two decades of experience in pharmaceutical finance management and operations. He comes to CANbridge from Sanofi China, where he held positions as Senior Director, Head of Business Controlling, China Pharma &CHC, and Pharma Controlling Director. Prior to Sanofi, Mr. Lau spent 18 years at GSK in Hong Kong and China, where he rose through the finance ranks to become Senior Finance Manager, GSK China.

Mr. Lau holds a Bachelor in Business Administration from the University of Wisconsin, Madison, Wisconsin. He is a certified public accountant, and a member of the AICPA and HKICPA.

Fangzhou Cheng has 18 years of experience in oncology sales and marketing and management of commercial products, most recently at Celgene China (later acquired by BeiGene) where she was Senior Director and Oncology Business Unit Head of Abraxane. Prior to her time at Celgene/BeiGene, Ms. Cheng was Sales Director, Pfizer China, responsible for all oncology products, including Sutent and Xalkori, and AstraZeneca China, where she held a number of oncology sales and marketing positions.

Ms. Cheng holds a Bachelor in Clinical Medicine from Shanghai University of Traditional Chinese Medicine, Shanghai, China.

"I am delighted to welcome Jeff and Fangzhou to the CANbridge Management team," said James Xue, PhD, Founder, Chairman and CEO, CANbridge Pharmaceutical. "With the recent Chinese market approval of Caphosol and the NDA submission for NERLYNX in China, CANbridge is taking its place as a commercial company poised to undergo a period of accelerated growth. I am confident that, together with the rest of the leadership, these two highly-accomplished executives will help build the critical infrastructure that will ensure the continued success of CANbridge."

About CANbridge Pharmaceutical Inc.

CANbridge Pharmaceutical Inc. is a China-based bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, focusing on products that are unavailable or address medical needs that are underserved in the region.

CANbridge has been widely recognized as a leader in orphan diseases in China, and has a partnership with WuXi Biologics to develop and commercialize proprietary therapeutics for the treatment of rare diseases. CANbridge also has exclusive rights to develop and commercialize Puma Biotechnology's NERLYNX® (neratinib) in China, Taiwan, Hong Kong and Macao (collectively, greater China); a license with Apogenix to develop and commercialize APG101 in greater China; a license (ex-North America) to develop and commercialize AVEO Oncology's  ErbB3 (HER3) inhibitory antibody candidate AV203 and an agreement with EUSA Pharma to commercialize Caphosol® for the prevention and treatment of oral mucositis caused by cancer treatments, for which it has received approval in China.

For more on CANbridge Pharmaceutical Inc., please go to www.canbridgepharma.com.

Contact:

CANbridge Pharmaceutical Inc.
James Xue        
CEO
+8610.8414.8018
781.995.0074

Media
Deanne Eagle
Planet Communications
[email protected] 
917.837.5866

SOURCE CANbridge Pharmaceutical Inc.

Related Links

http://www.canbridgepharma.com